GSA Capital Partners LLP Purchases 45,337 Shares of Codexis, Inc. (NASDAQ:CDXS)

GSA Capital Partners LLP increased its position in Codexis, Inc. (NASDAQ:CDXS) by 83.5% in the 3rd quarter, HoldingsChannel.com reports. The fund owned 99,629 shares of the biotechnology company’s stock after acquiring an additional 45,337 shares during the quarter. GSA Capital Partners LLP’s holdings in Codexis were worth $307,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other large investors also recently modified their holdings of the company. Los Angeles Capital Management LLC bought a new stake in Codexis during the second quarter valued at about $54,000. Marshall Wace LLP bought a new stake in Codexis during the second quarter valued at about $89,000. State Board of Administration of Florida Retirement System grew its holdings in Codexis by 57.4% during the first quarter. State Board of Administration of Florida Retirement System now owns 28,500 shares of the biotechnology company’s stock valued at $99,000 after purchasing an additional 10,395 shares during the period. SG Americas Securities LLC grew its holdings in Codexis by 72.6% during the second quarter. SG Americas Securities LLC now owns 36,677 shares of the biotechnology company’s stock valued at $114,000 after purchasing an additional 15,425 shares during the period. Finally, Algert Global LLC grew its holdings in Codexis by 17.1% during the second quarter. Algert Global LLC now owns 41,556 shares of the biotechnology company’s stock valued at $129,000 after purchasing an additional 6,069 shares during the period. Institutional investors own 78.54% of the company’s stock.

Codexis Price Performance

Shares of Codexis stock opened at $4.61 on Friday. The stock’s 50-day simple moving average is $3.42 and its 200-day simple moving average is $3.26. Codexis, Inc. has a 52 week low of $1.85 and a 52 week high of $4.91. The company has a market capitalization of $375.16 million, a price-to-earnings ratio of -5.30 and a beta of 2.07. The company has a quick ratio of 3.15, a current ratio of 3.21 and a debt-to-equity ratio of 0.39.

Codexis (NASDAQ:CDXS) last announced its quarterly earnings data on Thursday, October 31st. The biotechnology company reported ($0.29) EPS for the quarter, missing the consensus estimate of ($0.25) by ($0.04). Codexis had a negative net margin of 96.35% and a negative return on equity of 71.56%. The business had revenue of $12.83 million during the quarter, compared to analysts’ expectations of $11.64 million. During the same quarter in the previous year, the firm earned ($0.26) earnings per share. As a group, analysts expect that Codexis, Inc. will post -0.76 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

CDXS has been the subject of several recent research reports. Benchmark reissued a “hold” rating on shares of Codexis in a report on Monday, November 4th. Cantor Fitzgerald reissued an “overweight” rating and set a $11.00 price target on shares of Codexis in a report on Friday.

Insider Activity

In other news, major shareholder Opaleye Management Inc. bought 1,055,000 shares of the firm’s stock in a transaction that occurred on Friday, September 20th. The shares were bought at an average cost of $3.01 per share, for a total transaction of $3,175,550.00. Following the completion of the transaction, the insider now owns 8,390,000 shares of the company’s stock, valued at approximately $25,253,900. This represents a 14.38 % increase in their ownership of the stock. The purchase was disclosed in a legal filing with the SEC, which is available through the SEC website. Insiders have acquired 1,166,000 shares of company stock worth $3,514,910 over the last ninety days. Corporate insiders own 2.10% of the company’s stock.

Codexis Profile

Codexis, Inc discovers, develops, and sells enzymes and other proteins. The company operates through two segments, Performance Enzymes and Novel Biotherapeutics. It offers biocatalyst products and services. The company also provides biocatalyst screening and protein engineering services. In addition, it offers CodeEvolver, a technology platform, which helps in developing and delivering biocatalysts that perform chemical transformations and enhance the efficiency and productivity of manufacturing processes.